<DOC>
	<DOCNO>NCT00747786</DOCNO>
	<brief_summary>The purpose study , assess safety local tolerability long-term use Somatuline Autogel administer patient partner ( `` Home Injection Group '' ) safety local tolerability patient receive injection healthcare professional ( HCP ) ( `` Reference Group '' ) .</brief_summary>
	<brief_title>Non Interventional Post Marketing Programme Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>The patient must give write ( personally sign date ) inform consent data include database Post Marketing Surveillance programme subsequent analysis . The patient must receive treatment Somatuline Autogel stable dose least 4 month . The patient must diagnosis neuroendocrine tumour The patient must least 18 year age For patient receive intend receive Somatuline Autogel home injection : The patient must able store Somatuline Autogel safely refrigerator home either collect GP/Pharmacy monthly basis , receive medication home delivery service . The patient pregnant breastfeeding , unless continue treatment Somatuline Autogel clearly need ( determined treat clinician ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>